AbbVie's Rinvoq Hits the Mark in Pivotal Phase III Dermatitis Trial

AbbVie announced that its Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in the second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.